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Although Rho GTPases RhoA, RhoB, and RhoC share more than 85% amino acid 
sequence identity, they may play very distinct roles in tumor progression. RhoA and 
RhoC have been suggested in many studies to contribute positively to tumor progression, 
but the role of RhoB in cancer still remains unclear. RhoB contains a unique C-terminal 
region that undergoes specific post-translational modifications affecting its localization 
and function. In contrast to RhoA and RhoC, RhoB not only localizes at the plasma 
membrane, but also on endosomes, multivesicular bodies and has even been reported in 
the nucleus. Recent studies have shown that small GTPases such as RhoA, Rac1 and 
Cdc42 are induced in vitro during hypoxia. Hypoxia within a solid tumor arises from the 
increase in oxygen consumption of rapidly proliferating cancer cells, and a decrease in 
oxygen availability due to structurally and functionally abnormal blood vessels that form 
within these tumors. Although RhoA and RhoC are well characterized and have been 
extensively studied under hypoxia, whether and how hypoxia regulates RhoB remains 
elusive. 
We investigated the effect of hypoxia on the expression of RhoB and the 
mechanism and significance of RhoB expression in breast cancer. We found that hypoxia 
significantly upregulated the mRNA and protein expression of RhoB in a HIF-1 
independent manner in SUM159 and MDA-MB-231 cell lines. CRISPR-mediated 
reduction in RhoB expression caused a marked decrease in HIF-1α expression in an 
AKT-dependent manner, but did not show the reverse for RhoB overexpression. 
Therefore, we conclude that RhoB is necessary, but not sufficient for HIF-1 induction 




led to a small, but significant, decrease in cell motility and proliferation. Furthermore, 
orthotopic implantation of RhoB knockdown cells into immune-deficient mice 
contributed to a slower tumor growth and decreased metastasis compared to the wild type 
and non-targeted controls. Our work suggests that RhoB may play an oncogenic role in 
breast cancer potentially by increasing HIF-1α. This work warrants additional studies to 
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1.1 Breast Cancer Overview 
Breast cancer is the most common cancer that occurs in women. In 2017, more than 
250,000 new cases are expected to be diagnosed among women, equating to about 30% 
of all cancers1. This means that 1 in 8 women will develop invasive breast cancer during 
her lifetime. Additionally, breast cancer is still the 2nd leading cause of cancer-related 
deaths for women in the United States (Fig. 1). Although the number of deaths have 
decreased by 34% since 1990, in 2017, more than 40,000 women are still predicted to die 
from breast cancer1. A woman’s risk of breast cancer nearly doubles if she has a first-
degree relative who has also been diagnosed. About 5-10% of breast cancers can be 
linked to inherited gene mutations, most commonly in the BRCA1 and BRCA2 genes2. 
Upon diagnosis, the patient’s treatment options are determined by the presence or 
absence of three key receptors: ER, PR and HER2, as well as clinical staging based on 
size, lymph node involvement and tumor histology. Despite all of these evaluations, there 
are still no techniques of definitively identifying patients who will relapse or whose 
tumor will metastasize3. Consequently, there is still very little we can do to improve the 






Figure 1: Trends in age-adjusted cancer death rates by site, females, US, 1930-20141. 
According to the American Cancer Society, in 2016, breast cancer remains the second leading 
cause of death among women in the United States. 
 
1.1.1 Tumorigenesis 
Breast cancer arises when changes at the cellular, genetic, and epigenetic levels 
develop and abnormal cell division begins to occur. Normal cells are transformed into 
cancer cells and begin to proliferate rapidly and may even form a malignant mass. 
Usually, cell proliferation is balanced with apoptosis to maintain the integrity of tissues 
and organs. However, some cells develop mutations in their DNA that disrupt this 
process thereby upsetting this balance between cell growth and death. Mutations can 
include those that inactivate DNA repair genes, create an oncogene as well as inactivating 
many tumor suppressor genes. A series of several mutations to certain classes of genes is 
required before a normal cell will transform into a cancer cell4. 
There is no single cause of cancer development. Variants of inherited genes may 
predispose individuals to cancer. Additionally, environmental factors such as carcinogens 




these, random mistakes in normal DNA replication could also result in cancer causing 
mutations that are ultimately uncontrollable.  
 
1.1.2 Metastatic process 
Metastasis is the least understood process in tumorigenesis. Of the deaths 
attributed to cancer, 90% are due to metastasis, and treatments that prevent or cure 
metastasis remain elusive5. In most instances, primary tumors are successfully removed 
by surgery or treated with radiation. However, once the tumor cells begin to disseminate 
to other organs in the body, it is very difficult to treat and in most cases, leads to death.  
Metastasis consists of a series of rate-limiting steps. In order for the initiation 
process to begin, the tumor cells must acquire a motile phenotype, which is mediated by a 
process called the epithelial-mesenchymal transition (EMT). The cell can then detach 
from the primary, vascularized tumor, penetrate the surrounding tissue, enter nearby 
blood vessels (intravasation) and circulate in the vascular system (Fig. 2)6. Successful 
migration depends on the survival of circulating tumor cells (CTCs) in the blood 
circulation. Some of these cells eventually adhere to blood vessel walls and are able to 
extravasate and migrate into the local tissue, where they can form a secondary tumor in 
places like the lungs, liver, brain and bones. There has been an increasing amount of 







Figure 2: The metastatic process6. In a series of steps that comprise the metastatic process, 
cancer cells migrate or flow through very different microenvironments, including the stroma, the 
blood vessel endothelium, the vascular system and the tissue at a secondary site. 
 
1.2 Hypoxia 
1.2.1 Hypoxia and breast cancer   
About 25-40% of invasive breast cancers exhibit hypoxic regions7. On average, 
the partial pressure of oxygen (pO2) in normal human breast tissue is 65 mmHg (~8.5%), 
whereas human breast cancers have a median pO2 of 10 mmHg (~1/3%). Patients that 
have a primary tumor with pO2 of less than 10 mmHg are at an increased risk of 
metastasis and mortality, independent of any other factors8. 
Human cells require an adequate and continuous supply of oxygen for use as the 
terminal electron acceptor in the process of mitochondrial respiration that generates ATP, 
which is then used to power most biochemical reactions in the body9. Rapid cancer cell 
proliferation, combined with structural and function abnormalities in tumor blood vessels, 
results in regions within solid tumors that have reduced oxygen availability5. To adapt to 




mediated by HIFs. During this process, hypoxic cells obtain invasive and metastatic 
properties as well as resistance to chemotherapy and radiation therapy, which together 
constitute the lethal cancer phenotype7,9. 
 
1.2.2 Hypoxia Inducible Factors 
 The most well-characterized hypoxia response pathway is mediated by hypoxia-
inducible factor-1 (HIF-1). HIFs facilitate both oxygen delivery and adaptation to oxygen 
deprivation by regulating the expression of genes that are involved in many cellular 
processes, including glucose uptake and metabolism, angiogenesis, erythropoiesis, cell 
proliferation, and apoptosis10. HIF-1 is a heterodimer with a HIF-1β subunit that is 
constitutively expressed and an oxygen-dependent HIF-1α subunit.  
 In an O2-rich environment (Fig. 3), prolyl hydroxylases (PHDs) modify the 
Pro402 and Pro564 resides of HIF-1α and allow the VHL tumor suppressor protein to 
bind to HIF-1α, which leads to its ubiquitylation and proteasomal degradation. Under low 
oxygen conditions (Fig. 4), this degradation is inhibited and HIF-1α stabilizes and 
dimerizes with its beta subunit to bind with the hypoxia response element (HRE). By 
interacting with its coactivator, HIF-1 activates transcription of target genes, which aid in 
increase O2 delivery or facilitate metabolic adaptation to hypoxia and consequently tumor 
progression. Similar to HIF-1α, HIF-2α is also regulated by oxygen-dependent 
hydroxylation (Fig.4). HIF-1α and HIF-2α are structurally similar in DNA binding and 
dimerization domains, but differ in their transactivation domains11. HIF-2α also dimerizes 












tumorigenesis, including angiogenesis, metabolism, proliferation, metastasis and 
differentiation10. Data from clinical studies that are complemented with mice models, 
have demonstrated that HIF-1 has a key role in primary tumor growth and 
vascularization8. These studies showed that lung metastasis was severely decreased in 
HIF-1α knock-out mice. HIF-1α is known to be overexpressed in many cancer types and 
is associated with poor prognosis in breast, brain, oropharynx, cervix, ovary and uterus 
cancers11. Interestingly, HIF-1α is more highly expressed in metastases (69%) than with 
the actual primary tumor (29%)11. This could be one of the main reasons why metastasis 
results in such a poor patient outcome.  
 HIF-1 also regulates the expression of genes that encode proteins with key roles 
in cancer biology. This occurs when HIF-1α and HIF-2α bind and activate the 
transcription of many target genes with cis-acting hypoxia response elements that contain 
the consensus binding site 5’-RCGTG-3’13. These genes induced by hypoxia encode 
proteins that regulate angiogenesis, cell survival, chemotherapy and radiation resistance, 
genetic instability, immortalization, immune evasion, invasion and metastasis, 
proliferation, metabolism and pH regulation, and stem cell maintanence13.  
 
1.3 Rho GTPases 
1.3.1 Overview of Rho GTPases 
 Rho proteins are small molecules (~21 kDa) that belong to the Ras superfamily 
and function as binary switches in a wide variety of signaling pathways14. They consist of 
a family of 20 intracellular signaling molecules that are most well-known for their role in 




pathways that regulate gene transcription, vesicle trafficking and cytoskeletal 
reorganization, which are all processes that regulate growth, differentiation, adhesion, 
and migration of cells. In order to stimulate these pathways, the small GTPases must be 
in their active, GTP-bound conformation. Only in this state are they able to bind effector 
proteins and transduce signals from membrane receptors such as cytokine and growth 
factor receptors, integrins and G-protein coupled receptors15. 
 
 
Figure 5: The Rho-protein family16. The Rho family of proteins contain around 20 small 
GTPases that can be subdivided on the basis of functional, biochemical and sequence data. 
 
1.3.2 Rho GTPase Structure and Regulation 
 A structural feature that distinguishes the Rho proteins from other small GTPases 





 GTP-bound Rho proteins interact with many different effector molecules that 
influence their activity and localization. The regulation of these effector proteins is what 
eventually leads to changes in cell behavior. Many effector proteins are kinases, which 
phosphorylate cellular targets to control the behavior of the cell. The best-characterized 
effector kinases are the p21-activated kinases, which makes sense since they bind to 
active Cdc42 and Rac1 as well as the ROCKs, which bind active RhoA16. Another type 
of effector molecule are scaffold proteins, which operate through protein-protein 
interactions to control cellular functions. 
 
1.3.3 Rho Proteins and Cancer 
Ras proteins are mutated in 30% of human cancers with different origins, which 
hold the possibility that the same might be true for the Rho GTPase family. As of now 
though, no mutations have been reported in the Rho family. Since it is already established 
that Rho proteins have roles in the regulation of polarization, migration, proliferation and 
survival of cells, it was expected that a mutational activation or inactivation would be the 
cause of tumor formation and progression14,15,16–19. However, since no mutations have 
been found, deregulation of Rho GTPase signaling could instead occur at the level of 
expression or activation of Rho GTPases, accomplished by the level of expression or 
activation of their regulators or downstream effectors15. In vitro studies have shown that 
Rho-GEFs are more potent oncogenes that GTPase-defective Rho proteins, and that a fast 
GTP-GDP cycling mutant of Cdc42 has a greater transforming capacity than a GTPase-




outcome suggests the potential use of Rho-protein expression levels as prognostic 
indicators16. 
Even in normal, healthy cells, Rho GTPases are known for their involvement in 
cell morphology and motility. Cdc42 has a big role in extending the filopodia, which 
senses different signals and establishes the directionality of movement. Rac then 
assembles lamellipodia at the leading edge of the cell and RhoA generates a contractile 
force to push the cell forward. Besides having a deregulated proliferation process, tumor 
cells also have modified morphological features that allow them to cross through tissue 
boundaries and develop metastatic sites throughout the body. Given the role of Rho 
proteins in normal cell migration and their deregulation in cancer cells, it is likely that 
their role in the invasive phenotype of tumor cells is significant. As shown in Figure 7, 







Figure 7: Involvement of Rho proteins at different stages of tumor progression16. Rho 
proteins each have a distinct role in tumorigenesis, which allow the cells to proliferate and 
eventually become malignant. 
 
1.3.4 RhoB in Cancer 
Although Rho GTPases RhoA, RhoB, and RhoC share more than 85% amino acid 




RhoC have been suggested in many studies to contribute positively to tumor progression, 
but the role of RhoB in cancer still remains unclear21–23. RhoB has several additional 
features that are distinct among Rho proteins. Unlike most small GTPases, which are 
relatively stable, RhoB is turned over quickly, its synthesis rapidly upregulated by 
various growth and stress stimuli17. RhoB contains a unique C-terminal region that 
undergoes specific post-translational modifications affecting its localization and 
function18. In contrast to RhoA and RhoC, RhoB not only localizes at the plasma 
membrane, but also on endosomes, multivesicular bodies and has even been reported in 
the nucleus19. All of these characteristics ultimately contribute to the regulation of 
proliferation, survival, invasion and angiogenic capacity in some way by RhoB. 
 RhoB was first described to contribute to fibroblast transformation downstream of 
the Ras onco-protein, but more recently it has been described as contributing negatively 
to tumor growth19. There has been much controversy between different groups as to 
whether RhoB is a tumor promotor or suppressor. However, since there is evidence of 
RhoB being both overexpressed and downregulated in different cancers, it is highly likely 
that RhoB functions in a contextual manner, responding to specific signals in the tumor 
microenvironment.  
 
1.4 Interleukin-8 in Cancer 
IL-8 (CXCL8) is a proinflammatory cytokine that belongs to the CXC 
superfamily and was initially described as a neutrophil chemoattractant24. It is involved in 
many intracellular signaling pathways (Fig. 8) and its expression has been shown to be 




stresses like hypoxia, and steroid hormones. The biological effects of IL-8 are mediated 
through the binding of IL-8 to two cell-surface G protein-coupled receptors, CXCR1 and 
CXCR225. The expression of IL-8 receptors on cancer cells, endothelial cells, neutrophils, 
and tumor-associated macrophages indicates that the IL-8 secretion from cancer cells 
may have a profound effect on the tumor microenvironment25. Recent studies have shown 
that a variety of human tumor cells constitutively secrete IL-8. Additionally, IL-8 may 
promote the growth of several different types of cancer including non-small cell lung 
cancer, colorectal cancer, breast cancer, ovarian cancer, and may even correlate with their 
metastatic potential24. Targeting CXCR1/2 signaling has already been proven effective in 
in vivo models of breast cancer as well as primary invasive and metastatic breast cancers, 







Figure 8: Characterized IL-8 signaling pathways25. IL-8 signaling is involved in many 
different pathways that are influence in all aspects of the cell cycle. 
 
Phosphatidylinositol-3 kinase (PI3K) is one of the principle effectors of IL-8 
promoted chemotaxis of neutrophils, which results in increased phosphorylation of its 
substrate Akt. Increased Akt expression and activity have been identified in many types 
of cancer and its role in mediating cell survival, angiogenesis, and cell migration have 
been well-established as a crucial therapeutic target in cancer25. Activation of Akt by IL-8 





1.5 PI3K/Akt Pathway in Cancer 
 PI3Ks are heterodimeric lipid kinases that are composed of a regulatory and 
catalytic subunit that are encoded by different genes26. Akt is a serine/threonine specific 
kinase that is known to play an essential role in multiple cellular processes, such as cell 
growth, migration, survival, metabolism, angiogenesis, proliferation and others, which 
are all known to contribute to tumor progression27. Activation of Akt is involved in many 
pathways (Fig. 9) and plays a key role in fundamental cellular functions by 
phosphorylating a variety of substrates. The abnormal activation of the PI3K/Akt 
pathway has been shown in many studies as an essential step toward the initiation and 
maintenance of tumors28. Besides tumor initiation, it has also been found that disruption 
of this pathway also plays a role in the potential response of a tumor to cancer treatment.  
  
 
Figure 9: Schematic representation of the PI3K/Akt pathway and its main components28. 





 PI3Ks are activated receptor tyrosine kinases, and the deregulation of their 
function has been implicated in several human cancers. Akt is activated by recruitment to 
the plasma membrane through direct contact with PIP3 and phosphorylation at Thr308 
and Ser473. Thr308 is phosphorylated by the 3-phosphoinositide-dependent protein 
kinase PDK1, whereas Ser473 is phosphorylated by a molecularly unidentified kinase, 
PDK226. This PI3K/Akt has shown to be able to be activated by the low-molecular-
weight GTP/GDP binding GTPase Ras, which is found oncogenically mutated in 30% of 
all human cancers. The available clinical evidence of PI3K-pathway deregulation in 
many cancers and the identification of downstream kinases such as Akt, mTOR, PDK1 




It was previously published that HIFs activate RhoA and ROCK1 expression and 
signaling in breast cancer cells, which promoted an invasive phenotype characterized by 
enhanced migration and contractility under hypoxic but not control cell culture conditions 
12. RhoA and RhoC have been implicated in tumor progression with roles in almost every 
step in the tumor progression process, but the role of RhoB still remains unclear23,22. 
Recent studies have also shown that small GTPases such as RhoA, Rac1 and Cdc42 are 
induced in vitro during hypoxia. Additionally, RhoA and RhoC have been well-
characterized and extensively studied under hypoxia, however whether and how hypoxia 
regulates RhoB remains elusive29,21. Since RhoB has only been minimally studied and 




the role of hypoxia-regulated RhoB expression in breast cancer progression to understand 






















Materials and Methods 
2.1 Cell Culture 
MDA-MB-231, MDA-MB-175 and MDA-MB-468 cells were obtained from 
ATCC and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Sigma Aldrich, St. 
Louis, MO) supplemented with 10% (v/v) fetal bovine serum (FBS, Corning) and 1% 
penicillin-streptomycin (Invitrogen). SUM159 cells were kindly provided by the 
Sukumar lab and were cultured in Ham’s F12 medium supplemented with 5% (v/v) FBS, 
1% penicillin-streptomycin and 5% Insulin/Hydrocortisone. Cells were maintained in a 
humidified environment at 37ºC and 5% CO2 during culture and live cell imaging. 
Hypoxic cells were maintained at 37ºC in a modular incubator chamber (Billups-
Rothenberg) flushed with a gas mixture containing 1% O2, 5% CO2, and 94% N2. 
Phospho-Akt inhibitors (Wortmannin and LY294002) and phospho-Erk inhibitors 
(UO126 and PD98059) were obtained from Cell Signaling Technology (Danvers, MA). 
Concentrations used were 1 µM, 50 µM, 10 µM and 50 µM for Wortmannin, LY294002, 
UO126 and PD98059, respectively. 
 
2.2 Knockdown by CRISPR/Cas9 
LentiCRISPR v2 plasmid used for generating a CRISPR-Cas9 endonuclease 
was a gift from Feng Zhang (Broad Institute, Massachusetts Institute of Technology, 
Cambridge, MA, obtained via Addgene (Addgene plasmid #52961)). HIF-1α/2α and 
RhoB knockout by CRISPR/Cas9 was performed as previously described with slight 
modifications30. Insert oligonucleotides that include a guide RNA sequence were 




cloning site. After bacterial transformation and DNA purification, all plasmid constructs 
were confirmed by nucleotide sequencing. The LentiCRISPR v2 plasmids and a non-
targeted control were briefly co-transfected with 4 µg PsPAX2 and 1µg pMD2.G into a 
10 cm dish of 293T cells using PolyJet™ transfection reagent (SignaGen Laboratories, 
Rockville, MD) according to the manufacturer’s instructions. Media was refreshed 16-
24h following initial transfection. Filtered viral supernatant was collected 48h post media 
change and was added to SUM159 and MDA-MB-231 cells. Puromycin (0.5 µg/mL) was 
added to the medium of cells transduced for selection. After selection, cells were 
expanded and used for experiments. 
 
gRNA Forward Reverse 
NTC2 CACCGCACCACGGTCCATACATACA AAACTGTATGTATGGACCGTGGTGC 
RhoB-3 CACCGCACATAGTTCTCGAAGACGG AAACCCGTCTTCGAGAACTATGTGC 














Table 1: Insert oligonucleotide sequences used for CRISPR/Cas-9 gene knockout 
 
2.3 Overexpression by Gateway Cloning 
R77-E279 Hs.RHOB (provided by Dominic Esposito, NCI, Addgene plasmid 




(670-1) (Campeau et al, 2009, Addgene plasmid #17293) via LR recombination reaction. 
After bacterial transformation and DNA purification, all plasmid constructs were 
confirmed by nucleotide sequencing. This expression plasmid was transfected into 293T 
cells using PolyJet™ transfection reagent (SignaGen) according to the manufacturer’s 
instructions. Filtered viral supernatant collected 24 h posttransfection was added to 
SUM159 cells. Puromycin (0.5 µg/mL) was added to the medium of cells transduced for 
selection. After selection, cells were expanded and used for experiments. 
  
2.4 Reverse transcription (RT) and qPCR 
Total RNA was extracted using TRI Reagent (Zymo Research, Irvine, CA) and 
the Direct-zol™ RNA Mini Prep Plus kit (Zymo Research) according to the 
manufacturer’s instructions. One microgram of total RNA was used for first-strand DNA 
synthesis with the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). 
qPCR was performed using human specific primers and iTaq SYBR Green Universal 
Master Mix (Bio-Rad Laboratories). The expression of each target mRNA relative to 18S 
rRNA was calculated based on the threshold cycle (Ct) as 2-Δ(ΔCt), where ΔCt = Cttarget – 










Primer Forward Reverse 
RhoB GAGAACATCCCCGAGAAGTG CTTCCTTGGTCTTGGCAGG 
P4HA1 CCCTGAGACTGGAAAATTGACCACAGC GGGGTTCATACTGTCCTCCAACTCCA 
CA-IX GGATCTACCTACTGTTGAGGCT CATAGCGCGAATGACTCTGGT 
HK2 CCAGTTCATTCACATCATCAG CTTACACGAGGTCACATAGC 
IL-6 ACTCACCTCTTCAGAACGAATTG CCATCTTTGGAAGGTTCAGGTTG 
IL-8 AGGTGCAGTTTTGCCAAGGAG GCAGACTAGGGTTGCCAGATTTA 
18S hs GAGGATGAGGTGGAACGTGT AGAAGTGACGCAGCCCTCTA 
18S m+h CGGCGACGACCCATTCGAAC GAATCGAACCCTGATTCCCCGTC 
 
Table 2: Primer sequences used for real-time qPCR 
 
2.5 Western Blotting 
Cells were lysed in IGEPAL CA-630 buffer (150mM NaCl, 1% IGEPAL CA-
630, 50 mM Tris-HCl, pH 8.0 and protease inhibitors) for 10 min on ice, centrifuged for 
10 min at 13,000 rpm at 4°C and the insoluble debris were discarded. Whole cell lysates 
were fractionated by 12% SDS-PAGE and transferred to nitrocellulose membrane (Bio-
Rad). The membrane was incubated for 1 hour with 5% milk in TBS-T (Tris-buffered 
saline and 0.1% Tween-20) and then incubated overnight with primary antibodies diluted 
in blocking buffer. Antibodies against the following proteins were used: HIF-1α (BD 
Biosciences, San Jose, CA), HIF-2α (Novus Biologicals, Littleton, CO), RhoB (Santa 
Cruz Biotechnology, Dallas, TX), Actin (ProteinTech, Rosemont, IL), Phospho-Akt and 
Akt (Cell Signaling, Danvers, MA). The membrane was then washed and incubated with 




for 2 hours. After washing, the chemiluminescence signal was detected on an AZURE 
C300 using ECL (PerkinElmer, Waltham, MA). 
 
2.6 Animal Studies 
2.6.1 Orthotopic Implantation 
Female 5- to 7-week-old NOD-SCID (Charles Rivers Laboratories, Wilmington, 
MA) mice were used according to protocol approved by the Johns Hopkins University 
Animal Care and Use Committee. Mice were anesthetized, and 3 x 106 SUM159 cells or 
2 x 106 MDA-MB-231 cells resuspended in a 50:50 PBS: Matrigel solution were injected 
into the mammary fat pad (process shown in Fig. 10). Tumors were measured in three 
dimensions (a, b, and c), and volume (V) was calculated as V = abc x 0.52. Tumors, 
ipsilateral axillary lymph nodes, and lungs were harvested, formalin fixed, paraffin 
embedded and used for IHC staining. Agarose inflated lung sections were stained with 
hematoxylin and eosin to detect metastatic foci. Tumor tissue was used to isolate RNA 
for qPCR to quantify various gene expressions. Lung tissue was used to isolate genomic 






0.05% Tween 20) by heating at 85°C for 40 min and subsequently cooling at room 
temperature for 30 min.  
Immunohistochemistry was performed using the LSAB+ System HRP kit (Dako, 
Agilent Technologies, Santa Clara, CA) and RhoB antibody (Santa Cruz Biotechnology). 
Briefly, the slides were incubated in 3% H2O2 for 10 min to quench endogenous 
peroxidase activity; washed sequentially with H2O and PBS-T for 5 min; blocked in 1% 
BSA/PBS for 30 min; washed twice with PBS; and incubated with RhoB antibody at a 
1:500 dilution in 1% BSA/PBS for 1 hour. After three PBS-T washes, slides were 
incubated with Biotinylated Linker for 15 min, washed again with PBS-T and incubated 
with Streptavidin-HRP for 15 min. After another PBS-T wash, slides were incubated with 
substrate-chromogen solution for around 30 seconds and rinsed gently with water. 
Sections were counterstained with Mayer’s hematoxylin for 5 min; rinsed with water; 
dipped briefly in 0.1% sodium bicarbonate and rinsed again with water. The slides were 
then dehydrated with an increasing gradient of ethanol (70%, 80%, 95%, 100%), 
followed by xylene and mounted with Paramount agent. 
 
2.8 Motility Assays 
2.8.1 3D Cell Migration Assay 
Collagen matrices were prepared with soluble rat tail type I collagen in acetic acid 
(Corning) to achieve a final concentration of 1 mg/mL collagen. 1M NaOH was then 
added to normalize the pH to about 7.0. Remaining volume filled with a 1:1 ratio of 
reconstitution buffer [0.2 HEPES (Sigma-Aldrich), 0.26 M NaHCO3 (Sigma-Aldrich), 




plates and collagen gels were left to solidify for 1 hour in an incubator at 5% CO2 and 
37°C. Immediately following solidification, 500µl of cell culture medium was added on 
top of the gel. 
Cells were incubated for 1 hour before time-lapse movies were acquired. Cell 
movements over time were imaged using Biotek’s Lionheart F automated microscope at 
10X. Images were taken every 5 minutes for 13.5 hours. Cells in the time-lapse movies 
were tracked using MetaMorph software to calculate x- and y-coordinates at each time 
interval. 
 
2.8.2 APRW modeling for motility analysis 
APRW model analysis was performed as described in detail using MatLab (code 
available)31. 3D cell trajectory data were used to statistically profile cell migration using 
the mean squared displacement (MSD) which can be obtained from [x(t), y(t)] 
coordinates of cells with time (t). MSD(𝜏) = [x(t + 𝜏) – x(t)]2 + [y(t + 𝜏) – y(t)]2 where 𝜏 = 
5 min*frame number. Values of persistence and speed are obtained from APRW model 
fitting and expressed as speed (S) and persistence (P) of cells, which can be used to 
calculated total cell diffusivity (Dtot). Dtot = (Sp2Pp + Snp2Pnp)/4 where both speed (S) and 
persistence (P) are calculated along both the primary and nonprimary axes. 
 
2.9 PrestoBlue Proliferation Assay 
To generate the standard curve of proliferation rate of SUM159 cells, different 
numbers of cells (1000, 5000, 10000, 50000, 100000, and 200000) were seeded in 24-




reagent (Invitrogen) for 2 hours with 5% CO2 at 37°C. 200 µl of cell culture media with 
PrestoBlue reagent were collected in 96-well plates. The absorbance was measured using 
the Cytation 5 Cell Imaging Multi-Mode Reader (Biotek, Winooski, VT). 
 3000 cells were seeded in 24-well plates and cultured for 4 days. Cells were 
incubated with 100 µl PrestoBlue reagent for 2 hours with 5% CO2 at 37°C and 200 µl 
cell culture media and PrestoBlue reagent mixtures were collected in 96-well plates. 
Absorbance was measure as described above. 
 
2.10 ELISA 
To measure IL-8 secretion, IL-8 levels in culture supernatants were determined by 
using an ELISA kit (Abcam Human IL-8 ELISA kit, Cambridge, MA) according to 
manufacturer’s instructions. A monoclonal antibody specific for IL-8 was coated onto the 
wells of the strips provided. Samples, including standards of known IL-8 concentrations, 
controls as well as unknowns were pipetted into the wells. During the first incubation, the 
standards and samples were incubated with a biotinylated monoclonal antibody specific 
for IL-8. After washing, Streptavidin-HRP was added and incubated, which allowed the 
biotinylated antibody to bind. The wells were washed again and a TMB substrate solution 
was added, which acts on the bound enzyme to induce a color change. The intensity of 
this colored product is directional proportional to the concentration of IL-8 present in the 
samples. A curve of the absorbance versus the concentration of IL-8 in the standard wells 
was plotted. By comparing the absorbance of the samples with the standard curve, the 





2.11 Statistical Analysis 
The mean values ± standard error of mean (SEM) were calculated and plotted 
using GraphPad Prism (6, San Diego, CA) software. When appropriate, statistical 
analysis were performed to compare means, namely two-tailed unpaired t-tests, one-way 
and two-way ANOVA followed by Bonferroni post-tests to determine statistical 

















Results and Discussion 
3.1 Hypoxia induces RhoB expression on the RNA and protein level 
 To test whether RhoB was induced under hypoxic conditions, the gene 
expressions and protein levels of RhoB in three breast cancer cell lines, MDA-MB-175, 
SUM159, and MDA-MB-231, were compared under both normal tissue culture 
conditions (20% O2) and hypoxic conditions (1% O2). It was observed that in all three of 
these cell lines RhoB mRNA and protein expression was induced under hypoxia (Fig. 
11). Because MDA-MB-231 cells have a lower basal level of RhoB, a 10X higher 
exposure was used to image this blot. An immunoblot of SUM159 and MDA-MB-
231cells was performed to assess the levels of HIF-1α, HIF-2α and RhoB protein over a 
48-hour time period (Fig. 12). Like previously seen, HIF-1α peaks at 4 hours and then 
decreases to a steady state level following 24 hours of continuous exposure.  RhoB 
increases gradually under hypoxic stimulation. The graphs of fold change vs. time under 
hypoxia are a quantitative way of assessing induction levels based on densitometry of the 










3.2 Hypoxia-induced RhoB occurs in a HIF-1α independent manner 
 In order to find the mechanism by which hypoxia regulates RhoB, we began to 
look at possible upstream targets of RhoB. HIF-1 is known to regulate most genes under 
hypoxia, therefore HIF-1α and HIF-2α CRISPR-mediated knockdowns were used to 
check for RhoB mRNA and protein expression under 20% and 1% O2. If RhoB was 
downstream of HIF-1α/2α, its expression would be affected by the HIF-1α/2α 
knockdowns. However, both RhoB mRNA and protein expression did not decrease for 
these knockdown cell lines under hypoxic conditions when compared to the wild type 
(WT) and non-targeted controls (NTC2) (Fig. 13a, c, d, f). To verify that HIF-1α was 
knocked down, PCR was also run on P4HA1, which is a downstream target of HIF-1α. 
As shown in Figure 13b, e, the P4HA1 gene expression does not get induced in the HIF-
1α knockdowns as it does in the others, revealing successful knockdown. These results 








Figure 13: Hypoxia-induced RhoB expression is HIF-1α/2α independent. SUM159 cells 
expressing a CRISPR gDNA targeting HIF-1α and HIF-2α did not change RhoB expression at the 
a) mRNA c) or protein level under hypoxia. b) P4HA1 gene expression was checked to verify 
knockdown of HIF-1α. d-f) MDA-MB-231 cells showing the same results as a-c. 
 

























































































3.3 CRISPR-mediated reduction of RhoB causes a decrease in HIF-1 α 
expression 
To examine the functionality of RhoB, we created RhoB knockdown clones using 
CRISPR in both SUM159 and MDA-MB-231 cell lines. Before running any experiments, 
it is important to test the efficiency of the knockdowns. To ensure RhoB expression was 
reduced, we ran a western blot with the WT and NTC2 controls and compared the RhoB 
levels with the two RhoB knockdowns (RhoB-3 and RhoB-4) under 20% and 1% O2. 
Figure 14 shows two good clones with a significantly reduced RhoB expression. 
Interestingly, when RhoB was depleted, a significant decrease in HIF-1α and HIF-2α 
expression was also observed (Fig. 14c, d). To see if this was also true on the RNA level, 
quantitative PCR analysis was performed on P4HA1 and CA-IX, both downstream 
targets of HIF-1α (Fig. 14a, b). As expected, there are also notable decreases in these 
gene expressions under hypoxia when RhoB is knocked down. These results were 
consistent with those seen in the MDA-MB-231 cells (Fig. 14d). Based on these 





Figure 14: CRISPR-mediated reduction of RhoB expression caused a decrease in HIF-1α 
expression under hypoxia. a, b) P4HA1 and CA-IX mRNA levels were analyzed by qPCR in 
SUM159 cells expressing a CRISPR gDNA targeting RhoB under 20% and 1% O2 for 24H. c) 
Immunoblot assays were also performed on c) SUM159 and d) MDA-MB-231 lysates to assess 
levels of HIF-1α, HIF-2α and RhoB exposed to 20% or 1% O2 for 48H.  
 
 If a decrease in RhoB expression simultaneously caused a reduced HIF-1α level, 
the reverse should be seen when RhoB is overexpressed. To investigate this hypothesis, 
SUM159 cells were transduced by a vector overexpressing RhoB. To validate the 
overexpressed cell line, a western blot was run for HIF-1α and RhoB protein levels under 
both normoxic and hypoxic conditions (Fig. 15a). Instead of seeing an increase in HIF-1α 
expression as expected, there is actually a slight decrease with the overexpressed RhoB 
cell lines. To verify this, gene expression of HIF-1α downstream targets, P4HA1 and CA-
















































IX, were analyzed by real time-PCR (Fig. 15b, c). From these graphs, it is clear that the 
results match those from the western. The gene expression of P4HA1 and CA-IX are not 
overexpressed with an increased RhoB level. After all of this, we can conclude that RhoB 
is necessary, but not sufficient for HIF-1 induction under hypoxia. 
 
 
Figure 15: RhoB overexpression does not lead to an increase in HIF-1α. a) Immunoblot assay 
was performed on SUM159 subclones containing a vector overexpressing RhoB to assess levels 
of HIF-1α, HIF-2α and RhoB exposed to 20% or 1% O2 for 48H. b, c) P4HA1 and CA-IX mRNA 
levels were analyzed by qPCR in the same subclones under 20% and 1% for 24H. 
 
3.4 Loss of RhoB leads to a decrease in cell motility and proliferation in 3D 
environments  
 RhoB is known to contribute to enhanced morphology and cell motility, two 
crucial components in the process of tumor progression. Because of this, we embedded 
MDA-MB-231 wild type, non-targeted control and both RhoB knockdown cell lines into 
a 













































a 3D collagen matrix and tracked their movement over a 16-hour time period. By doing 
this, our goal was to understand the role of RhoB in cancer cell motility and how it is 
involved in the metastatic cascade. With the x, y coordinates obtained from Metamorph, 
the average cell velocities (Fig. 16a) as well as the total cell diffusivities (Fig. 16b) were 
calculated as previously described22. From this, a small, but significant decrease in the 
velocity and a larger reduction in total cell diffusivity was noted. By plotting the 3D 
trajectories of each cell, we could visualize their movement with respect to each 
condition (Fig. 16c). It is clear that the RhoB knockdown cells had a much less spread out 
migration profile than the wild type and non-targeted controls. Because total cell 
diffusivity is calculated using both speed (S) and persistence (P), it appears that although 
the knockdowns did have a slightly slower average velocity, it is really the decreased 




























3.5 RhoB contributes to a slower tumor growth and decreased metastasis in 
vivo 
To explore the role of RhoB in vivo and how it affects tumor growth and 
metastasis, we orthotopically implanted 3 x 106 SUM159 and 2 x 106 MDA-MB-231 into 
the mammary fat pad of NOD-SCID mice. Tumor growth was measured over the course 
of 1-1.5 months and volume was compared between the WT, NTC2, RhoB-3 and RhoB-
4. The time it took for the tumor volume to reach 1000 mm3 was used to construct a 
Kaplan-Meier analysis curve (Fig. 18a). Although the RhoB-3 knockdown showed 
slightly better results than the RhoB-4, the knockdowns clearly have a slower tumor 
growth than the parental controls. Previously, it was found that a similar result was seen 
with the HIF-1α and HIF-2α knockdowns in mice8. Based on these observations, we 
show that RhoB knockdown cells show slower tumor growth in mice, similar to that of 
the HIF-1α. 
Tumor sections were subjected to IHC using an antibody against RhoB to verify 
these tumors still had a reduced RhoB expression (Fig. 18c). When compared to the 
NTC, there is barely any RhoB staining in the RhoB-3 and a small amount around in the 
necrotic regions in the RhoB-4 subclone. Tumor tissue was also saved for qPCR analysis 
of human RhoB content (Fig. 18d), which quantitatively shows what is seen in the 
immunohistochemistry staining. P4HA1 gene expression (Fig. 18e) was also analyzed via 
qPCR to correlate with our in vitro results that a decrease in RhoB downregulates HIF-1α 
downstream targets. These conclusions are also consistent with our tumor growth curves 
in that RhoB-3 has a more reduced RhoB expression, which corresponds with a slower 


























































Figure 18: RhoB promotes tumor growth of SUM159 and MDA-MB-231 cells. a) The 
indicated subclones of SUM159 were injected into the MFP of NOD-SCID mice and tumor 
volume was plotted as a Kaplan-Meier analysis of percent survival (V=a*b*c*0.52, 1 
being >1000 mm3) b) The indicated subclones of MDA-MB-231 were injected into the MFP of 
NOD-SCID mice and tumor volume was measured in three dimensions a, b, c (V=a*b*c*0.52). 
c) Tumor sections (scale bar = 100 µm) were subjected to IHC using an antibody against RhoB. 
d) Human RhoB content in tumors were quantified by qPCR. e) P4HA1 gene expression was also 
quantified by qPCR. 
 
 Since both migration and invasion are two critical steps in the metastatic cascade, 
we compared the overall metastatic burden resulting from control tumors or tumors 
lacking RhoB. To do this, we isolated genomic DNA from the mouse lung for analysis of 
human DNA by quantitative real-time PCR (Fig. 19a). Inhibition of RhoB expression in 
tumors significantly decreased lung metastasis. Lung metastasis was also assessed 
histologically by hematoxylin and eosin (H&E) staining (Fig. 19b). The number of 
metastatic foci per field of view in each section confirmed the qPCR results. We also 
assessed breast cancer cell infiltration of the ipsilateral axillary lymph node by H&E 
staining. The lymph nodes of the mice bearing control tumors were enlarged and 
completely invaded with cancer cells, whereas a more normal follicular structure and size 







































































Figure 19: RhoB promotes metastasis of SUM159 and MDA-MB-231 cells a) Lung sections 
(scale bar = 200 µm) were stained with hematoxylin and eosin to identify metastatic foci. b) 
Human genomic DNA content in lungs were quantified by qRT-PCR for human HK2 gene 
sequences. c) Lymph node sections (scale bar = 1000 µm) were stained with H&E to identify 
metastatic foci. White arrows indicate lymph cells and blue arrows indicate the invading tumor 
cells. 
 
3.6 Inhibition of IL-8R results in a decreased RhoB expression 
 From previous work, we investigated the effect of blocking IL-6R and IL-8R with 
inhibitors, Tocilizumab and Reparixin respectively, on 3D cell motility and in vivo tumor 
growth and metastatic potential. We found that using these inhibitors in MDA-MB-231 
cells resulted in a reduced RhoB mRNA expression as well both in vivo (Fig. 20a) and in 





















Figure 20: IL-8 receptor inhibition decreases RhoB expression both in vivo and in vitro. a) 
RhoB gene expression in MDA-MB-231 tumors were analyzed via qRT-PCR where mice were 
dosed with either saline (control), Tocilizumab (IL-6R inhibitor), Reparixin (IL-8R inhibitor) or a 
combination of both. b) RhoB gene expression in MDA-MB-231 cells analyzed by qRT-PCR 
under the same conditions except in 3D collagen matrices. 
 
 We hypothesized that IL-6 and/or IL-8 might be regulators of RhoB expression 
and could potentially be induced by hypoxic conditions. To test this hypothesis MDA-
MB-175, SUM159, MDA-MB-468 and MDA-MB-231 cells were exposed to 20% or 1% 
O2 for 24H. IL-6 and IL-8 mRNA expression was evaluated using qRT-PCR. Increased 
gene expressions were seen for IL-8, but not IL-6 when exposed to hypoxia (Fig. 21 a, b). 
Since IL-6 was not enhanced under hypoxic conditions at the RNA level, only IL-8 was 
used for further experiments.  IL-8 is a secreted protein. ELISA assays are commonly 
used to assess the level of secreted proteins and therefore was used to measure the 
concentration IL-8 in the conditioned media of MDA-MB-175, MDA-MB-231 and 
SUM159 cells under both hypoxic and normoxic conditions. SUM159 HIF-1α/2α 
knockdowns were used to evaluate the role of HIF-1/2α in IL-8 induction as we 
hypothesized that the secreted IL-8 levels should not change in the presence or absence of 
HIF-1α, but would still be enhanced under hypoxic conditions. However, instead of 







































seeing an increase in the amount of produced IL-8 under 1% O2, there was actually a 
decrease in every sample tested (Fig. 21c). This could be due to several factors. It is 
possible that IL-8 protein is not upregulated under hypoxia and, in turn, affecting RhoB 
in a separate, hypoxia-independent pathway. It is very clear that RhoB is influenced in 
some way by the IL-6 and IL-8 receptors, however most likely by a different mechanism. 
Alternatively, IL-8 and its receptor, CXCR2 are known to have a autocrine signaling 
feedback loop that is essential for eliciting the tumorigenicity of triple-negative breast 
cancer cells32. It is possible that under hypoxia, the cell is taking up IL-8 at a faster rate 
than it is being produced. This could explain a decrease in secreted IL-8 levels but an 
increase in IL-8 mRNA levels under hypoxia. Future experiments that examine the IL-
8/CXCR2 signaling cascade will help us examine the interplay between hypoxia and IL-8 






Figure 21: IL-8 mRNA is induced under hypoxia, but not the secreted IL-8.  a) IL-6 and b) 
IL-8 mRNA levels were analyzed by qRT-PCR in MDA-MB-175, SUM159, MDA-MB-468 and 
MDA-MB-231 breast cancer cell lines exposed to 20% or 1% O2 for 24H. c) Production of IL-8 
protein by human breast cancer cells under 20% and 1% O2 was determined by ELISA. 
 
3.7 RhoB affects HIF-1α expression in an Akt-dependent manner 
 Many published reports suggest that PI3K and Akt could play a major role in 
regulating the stabilization of HIF-1α in hypoxia33,34, although the PI3K/Akt signaling 
pathway by hypoxia seems to be cell type-specific. Some authors have also found that 
PI3K/Akt is activated by hypoxia35. Additionally, in both tumor cells and stromal 









































































































endothelial cells, RhoB function has been linked to the regulation of PI3K/Akt survival 
pathways36. In order to see which of these pathways were true in our system, we first 
treated SUM159 cells with phospho-Akt inhibitors (Wortmannin and LY294002) and 
phospho-Erk inhibitors (UO126 and PD98059) as controls. When SUM159 cells were 
treated with p-Akt, but not p-Erk inhibitors, the HIF-1α expression decreased under 
hypoxia (Fig. 22a). Inhibiting p-Akt does not affect RhoB expression (Fig. 22a). Next, we 
hypothesized that pAkt may require RhoB. To assess the contribution of RhoB to 
phospho-Akt, we assessed the level of phosphorylated Akt in the RhoB knockdown cells 
under 20% and 1% O2 conditions (Fig. 22b). Interestingly, when RhoB expression was 
abrogated, p-Akt expression was significantly reduced. These results illustrate that under 











Figure 22: RhoB leads to AKT phosphorylation. a) Immunoblot of SUM159 cells treated for 
1H prior to hypoxic stimulation with either DMSO, p-ERK inhibitor (UO126 and PD98059) or p-
AKT inhibitor (Wortmannin and LY294002) to assess levels of HIF-1α, HIF-2α, phospho-AKT, 
AKT and RhoB under 20% and 1% O2 for 4H. b) Immunoblot of RhoB knockdown subclones to 














The study described has highlighted a novel role for RhoB in the regulation of a 
new pathway controlled by hypoxia in breast cancer cells, SUM159 and MDA-MB-231. 
We found that hypoxia upregulates RhoB expression, which in turn initiates the 
phosphorylation of Akt and thereby increases HIF-1α expression (Fig. 23). We also 
demonstrated that RhoB contributes to an increased cell motility, total cell diffusivity and 
proliferation in a 3D setting. Correlating these results with an in vivo environment, we 
illustrate that RhoB promotes tumor growth and metastasis to the lungs and lymph nodes. 
Our work suggests that RhoB may play an oncogenic role in breast cancer, potentially by 
increasing HIF-1α under hypoxic conditions. This work warrants additional studies to 
determine whether targeting RhoB could have implications in the treatment of breast 
cancer, especially in patients with hypoxic tumors. 
 
 
Figure 23: The current hypoxia  RhoB  AKT  HIF-1α pathway. Hypoxia upregulates 











 Further research will be done to identify the exact mechanism by which hypoxia 
upregulates RhoB. As of now, there are no available studies that explain this connection 
in breast cancer. Being able to establish this link could help to justify whether targeting 
RhoB with therapeutic agents such as FTIs, antagonists of Ras-dependent neoplastic 
transformation, or HDAC inhibitors would be beneficial. Additionally, in order to better 
quantify metastatic potential in our in vivo model, we will stain the lymph nodes with 
human vimentin and count metastatic foci. We are also in the process of completing 
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